NO319829B1 - Preparat for diagnostisering av metabolsk syndrom samt sykdommer som omfatter syndromet - Google Patents
Preparat for diagnostisering av metabolsk syndrom samt sykdommer som omfatter syndromet Download PDFInfo
- Publication number
- NO319829B1 NO319829B1 NO19975492A NO975492A NO319829B1 NO 319829 B1 NO319829 B1 NO 319829B1 NO 19975492 A NO19975492 A NO 19975492A NO 975492 A NO975492 A NO 975492A NO 319829 B1 NO319829 B1 NO 319829B1
- Authority
- NO
- Norway
- Prior art keywords
- cortisol
- dexamethasone
- dose
- agonist
- use according
- Prior art date
Links
- 208000001145 Metabolic Syndrome Diseases 0.000 title claims abstract description 16
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title claims abstract description 16
- 238000003745 diagnosis Methods 0.000 title claims abstract description 4
- 208000030159 metabolic disease Diseases 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 122
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 61
- 239000000556 agonist Substances 0.000 claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 10
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 8
- 206010020772 Hypertension Diseases 0.000 claims abstract description 7
- 210000004369 blood Anatomy 0.000 claims abstract description 6
- 239000008280 blood Substances 0.000 claims abstract description 6
- 229960003957 dexamethasone Drugs 0.000 claims description 24
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 24
- 210000002966 serum Anatomy 0.000 claims description 10
- 208000004611 Abdominal Obesity Diseases 0.000 claims description 9
- 206010065941 Central obesity Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 210000003296 saliva Anatomy 0.000 claims description 6
- 239000003862 glucocorticoid Substances 0.000 claims description 4
- 239000002395 mineralocorticoid Substances 0.000 claims description 4
- 150000001886 cortisols Chemical class 0.000 claims description 3
- 230000002567 autonomic effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 abstract description 2
- 239000003925 fat Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 description 8
- 208000008589 Obesity Diseases 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102100021752 Corticoliberin Human genes 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229940098777 Corticosteroid agonist Drugs 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical class O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
- Combined Controls Of Internal Combustion Engines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9501991A SE505391C2 (sv) | 1995-05-30 | 1995-05-30 | Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet |
| PCT/SE1996/000708 WO1996038179A1 (en) | 1995-05-30 | 1996-05-30 | Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO975492D0 NO975492D0 (no) | 1997-11-28 |
| NO975492L NO975492L (no) | 1998-01-27 |
| NO319829B1 true NO319829B1 (no) | 2005-09-19 |
Family
ID=20398470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19975492A NO319829B1 (no) | 1995-05-30 | 1997-11-28 | Preparat for diagnostisering av metabolsk syndrom samt sykdommer som omfatter syndromet |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6410339B1 (de) |
| EP (1) | EP0835138B1 (de) |
| JP (1) | JPH11505850A (de) |
| CN (1) | CN1078479C (de) |
| AT (1) | ATE235258T1 (de) |
| AU (1) | AU716671B2 (de) |
| BR (1) | BR9608683A (de) |
| CA (1) | CA2222215A1 (de) |
| DE (1) | DE69626982T2 (de) |
| DK (1) | DK0835138T3 (de) |
| ES (1) | ES2189872T3 (de) |
| NO (1) | NO319829B1 (de) |
| PT (1) | PT835138E (de) |
| RU (1) | RU2171471C2 (de) |
| SE (1) | SE505391C2 (de) |
| WO (1) | WO1996038179A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217505B2 (en) * | 1998-02-26 | 2007-05-15 | Cortendo Ab | Method for determining whether condition is symptom of metabolic syndrome |
| SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| US20040220190A1 (en) * | 2002-07-29 | 2004-11-04 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
| US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| US20080200453A1 (en) | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
| US20040081678A1 (en) * | 2002-08-09 | 2004-04-29 | Anthony Cincotta | Therapeutic process for the treatment of obesity and associated metabolic disorders |
| US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
| US8137994B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
| US20050215558A1 (en) * | 2004-03-25 | 2005-09-29 | Cincotta Anthony H | Methods of identifying responders to dopamine agonist therapy |
| US8137993B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
| US20050232911A1 (en) * | 2004-04-19 | 2005-10-20 | Schreiber Brian D | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid |
| DE102004034640A1 (de) | 2004-07-16 | 2006-02-16 | Institut für Molekular- und Systemmedizin | Verfahren zur systemischen Biokorrektur eines Organismus |
| RU2367950C2 (ru) * | 2005-03-28 | 2009-09-20 | Ижевский государственный технический университет | Способ прогнозирования развития метаболического синдрома при артериальной гипертонии у мужчин |
| US20090117660A1 (en) * | 2005-04-30 | 2009-05-07 | Oakville Hong Kong Co., Limited | Devices and methods for sample collection and analysis |
| RU2321354C2 (ru) * | 2006-04-21 | 2008-04-10 | Анатолий Николаевич Дмитриев | Способ диагностики стадий метаболического синдрома |
| JP2010505420A (ja) * | 2006-10-06 | 2010-02-25 | ネステク ソシエテ アノニム | 生理的健康の生物学的媒介物質を測定するための組成物及び多重アッセイ |
| RU2336807C1 (ru) * | 2007-05-30 | 2008-10-27 | Виктория Борисовна Мычка | Способ диагностики метаболического синдрома |
| US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
| RU2403868C1 (ru) * | 2009-07-07 | 2010-11-20 | Учреждение Российской академии медицинских наук Дальневосточный научный центр физиологии и патологии дыхания Сибирского отделения Российской академии медицинских наук (ДНЦ ФПД СО РАМН) | Способ оценки риска развития метаболического синдрома у больных хроническим холециститом |
| RU2444298C1 (ru) * | 2010-07-15 | 2012-03-10 | Учреждение Российской академии медицинских наук Научный центр клинической и экспериментальной медицины Сибирского отделения РАМН (НЦКЭМ СО РАМН) | Способ диагностики метаболического синдрома |
| CN105973881A (zh) * | 2016-04-27 | 2016-09-28 | 樊福好 | 一种检测机体活度的溶液及检测方法 |
-
1995
- 1995-05-30 SE SE9501991A patent/SE505391C2/sv not_active IP Right Cessation
-
1996
- 1996-05-30 ES ES96916423T patent/ES2189872T3/es not_active Expired - Lifetime
- 1996-05-30 CA CA002222215A patent/CA2222215A1/en not_active Abandoned
- 1996-05-30 JP JP8536000A patent/JPH11505850A/ja not_active Ceased
- 1996-05-30 CN CN96194229A patent/CN1078479C/zh not_active Expired - Fee Related
- 1996-05-30 AT AT96916423T patent/ATE235258T1/de not_active IP Right Cessation
- 1996-05-30 WO PCT/SE1996/000708 patent/WO1996038179A1/en not_active Ceased
- 1996-05-30 DK DK96916423T patent/DK0835138T3/da active
- 1996-05-30 PT PT96916423T patent/PT835138E/pt unknown
- 1996-05-30 EP EP96916423A patent/EP0835138B1/de not_active Expired - Lifetime
- 1996-05-30 US US08/952,638 patent/US6410339B1/en not_active Expired - Fee Related
- 1996-05-30 AU AU59173/96A patent/AU716671B2/en not_active Ceased
- 1996-05-30 DE DE69626982T patent/DE69626982T2/de not_active Expired - Fee Related
- 1996-05-30 RU RU97121292/14A patent/RU2171471C2/ru not_active IP Right Cessation
- 1996-05-30 BR BR9608683-1A patent/BR9608683A/pt not_active Application Discontinuation
-
1997
- 1997-11-28 NO NO19975492A patent/NO319829B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK0835138T3 (da) | 2003-07-21 |
| SE9501991D0 (sv) | 1995-05-30 |
| BR9608683A (pt) | 1999-12-07 |
| US6410339B1 (en) | 2002-06-25 |
| PT835138E (pt) | 2003-08-29 |
| WO1996038179A1 (en) | 1996-12-05 |
| ATE235258T1 (de) | 2003-04-15 |
| RU2171471C2 (ru) | 2001-07-27 |
| EP0835138B1 (de) | 2003-03-26 |
| AU716671B2 (en) | 2000-03-02 |
| MX9709234A (es) | 1998-10-31 |
| ES2189872T3 (es) | 2003-07-16 |
| DE69626982D1 (de) | 2003-04-30 |
| CA2222215A1 (en) | 1996-12-05 |
| SE505391C2 (sv) | 1997-08-18 |
| EP0835138A1 (de) | 1998-04-15 |
| CN1185743A (zh) | 1998-06-24 |
| CN1078479C (zh) | 2002-01-30 |
| JPH11505850A (ja) | 1999-05-25 |
| NO975492D0 (no) | 1997-11-28 |
| AU5917396A (en) | 1996-12-18 |
| DE69626982T2 (de) | 2004-03-04 |
| SE9501991L (sv) | 1996-12-01 |
| NO975492L (no) | 1998-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6410339B1 (en) | Preparation for diagnosis of the metabolic syndrome and diseases including the syndrome | |
| Tarkun et al. | Association between circulating tumor necrosis factor-alpha, interleukin-6, and insulin resistance in normal-weight women with polycystic ovary syndrome | |
| Hofmann et al. | Inhibin-B: the physiologic basis of the clomiphene citrate challenge test for ovarian reserve screening | |
| Goland et al. | Elevated levels of umbilical cord plasma corticotropin-releasing hormone in growth-retarded fetuses | |
| Houdeau et al. | Sex steroid regulation of macrophage migration inhibitory factor in normal and inflamed colon in the female rat | |
| Nieman et al. | The ovine corticotropin-releasing hormone (CRH) stimulation test is superior to the human CRH stimulation test for the diagnosis of Cushing's disease | |
| Armanini et al. | Alzheimer’s disease: pathophysiological implications of measurement of plasma cortisol, plasma dehydroepiandrosterone sulfate, and lymphocytic corticosteroid receptors | |
| Grulet et al. | Study of the rate of early glucose disappearance following insulin injection: insulin sensitivity index | |
| Wodarz et al. | Normal lymphocyte responsiveness to lectins but impaired sensitivity to in vitro glucocorticoids in major depression | |
| Demir et al. | Serum leptin level in women with unexplained infertility | |
| Ferrier et al. | Gonadotrophin secretion abnormalities in chronic schizophrenia | |
| Roberts et al. | Adrenal function after upper femoral fracture in elderly people: persistence of stimulation and the roles of adrenocorticotrophic hormone and immobility | |
| Shokri et al. | Effect of exercise and detraining on signs of puberty and selected inflammatory markers in girls with precocious puberty | |
| Sumino et al. | Effects of hormone replacement therapy on office and ambulatory blood pressure in Japanese hypertensive postmenopausal women | |
| US7217505B2 (en) | Method for determining whether condition is symptom of metabolic syndrome | |
| Hasan et al. | The Effect of Body Weight Gain with or Without Diabetes Type 2 on the Levels of Noradrenalin and Some Neurotrophins. | |
| Hoeldtke et al. | Adrenomedullin concentrations in umbilical cord plasma of uncomplicated term pregnancies | |
| Khattak et al. | Comparison of Estradiol levels in Polycystic Ovary Syndrome and non-Polycystic Ovary Syndrome Infertile Patients | |
| MXPA97009234A (en) | Preparation for the diagnosis of the metabolic syndrome and diseases that include the sindr | |
| JP4044842B2 (ja) | 肥満を処置し得る薬剤のスクリーニング法 | |
| Meijin et al. | A3081 VDR agonist prevents diabetic endothelial dysfunction through inhibition of prolyl isomerase-1 mediated mitochondrial oxidative stress and inflammation | |
| Abd Alkhalik et al. | Association of soluble E-selectin and morning blood pressure surge in patients with essential hypertension | |
| Mushtaq et al. | Role Of Melatonin In Regulation Of Menstrual Cycle In Women With Polycysic Ovarian Syndrom (PCOS) | |
| Otta et al. | Serum adiponectin levels in different phenotypes of polycystic ovary syndrome | |
| Buffa et al. | The assessment of protein energy malnutrition in elderly people |